中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (1): 16-21.doi: 10.35541/cjd.20220390
中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业组
收稿日期:2022-06-01
修回日期:2022-11-07
发布日期:2023-01-03
通讯作者:
李吉；宋为民
E-mail:liji_xy@csu.edu.cn; doctorsong@126.com
Rosacea Research Center, Chinese Society of Dermatology; Rosacea Professional Committee, China Dermatologist Association
Received:2022-06-01
Revised:2022-11-07
Published:2023-01-03
Contact:
Li Ji; Song Weimin
E-mail:liji_xy@csu.edu.cn; doctorsong@126.com
摘要： 【摘要】 A型肉毒毒素是一种神经毒素，广泛用于皮肤美容。有证据表明，皮内注射A型肉毒毒素能改善玫瑰痤疮患者面部皮肤潮红及持续性红斑，但对治疗浓度、剂量、操作方法、疗程、治疗间隔等均存在差异。中华医学会皮肤性病学分会玫瑰痤疮研究中心、中国医师协会皮肤科分会玫瑰痤疮专业组在玫瑰痤疮诊疗指南的基础上，参考新近文献并结合诸多专家临床应用经验撰写本共识，为A型肉毒毒素皮内注射治疗玫瑰痤疮提供更科学、规范的参考依据。
中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业组. A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识[J]. 中华皮肤科杂志, 2023,56(1):16-21. doi:10.35541/cjd.20220390
Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, China Dermatologist Association. Expert consensus on intradermal injections with botulinum toxin A for the treatment of flushing and persistent erythema caused by rosacea[J]. Chinese Journal of Dermatology, 2023, 56(1): 16-21.doi:10.35541/cjd.20220390
| ［1］ | Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA［J］. J Drugs Dermatol, 2012,11（12）:e76⁃e79. |
| ［2］ | 张二佳, 林彤. A型肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（9）:610⁃613. doi: 10.12144/zgmfskin202109610. |
| ［3］ | 曾黛琳, 于波, 吴琳. 肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 实用皮肤病学杂志, 2021,14（5）:297⁃300. doi: 10.11786/sypfbxzz.1674⁃1293.20210510. |
| ［4］ | Bloom BS, Payongayong L, Mourin A, et al. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea［J］. Dermatol Surg, 2015,41 Suppl 1:S9⁃16. doi: 10.1097/DSS. 0000000000000277. |
| ［5］ | Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double⁃blind, placebo⁃controlled, split⁃face pilot study in rosacea patients with facial erythema［J］. Dermatol Surg, 2019,45（9）:1155⁃1162. doi: 10. 1097/DSS.0000000000001819. |
| ［6］ | Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type a⁃⁃evidence⁃based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications［J］. Plast Reconstr Surg, 2016,137（3）:518e⁃529e. doi: 10.1097/01.prs. 0000475758.63709.23. |
| ［7］ | 中华医学会整形外科学分会微创美容专业学组. A型肉毒毒素用于面部医学美容的临床专家共识［J］. 中华整形外科杂志, 2018,34（10）:791⁃795,802. doi: 10.3760/cma.j.issn.1009⁃4598.2018.10.001. |
| ［8］ | 中国医师协会皮肤科医师分会注射美容亚专业委员会. 肉毒毒素注射在皮肤美容中应用的专家共识［J］. 中国美容医学, 2017,26（8）:3⁃8. |
| ［9］ | 肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识［J］. 中华神经科杂志, 2018,51（10）:779⁃786. doi: 10.3760/cma.j.issn.1006⁃7876.2018.10.002. |
| ［10］ | Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2018,78（1）:148⁃155. doi: 10.1016/j.jaad.2017.08.037. |
| ［11］ | Thiboutot D, Anderson R, Cook⁃Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2020,82（6）:1501⁃1510. doi: 10.1016/j.jaad.2020.01. 077. |
| ［12］ | 中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）［J］. 中华皮肤科杂志, 2021,54（4）:279⁃288. doi: 10.35541/cjd.20201078. |
| ［13］ | 汪犇, 赵志祥, 简丹, 等. 中国玫瑰痤疮临床特征分析和诊断标准再探讨［J］. 中华皮肤科杂志, 2020,53（9）:675⁃679. doi: 10.35541/cjd.20200376. |
| ［14］ | Schaller M, Dirschka T, Lonne⁃Rahm SB, et al. The importance of assessing burning and stinging when managing rosacea: a review［J］. Acta Derm Venereol, 2021,101（10）:adv00584. doi: 10.2340/actadv.v101.356. |
| ［15］ | Tan J, Steinhoff M, Bewley A, et al. Characterizing high⁃burden rosacea subjects: a multivariate risk factor analysis from a global survey［J］. J Dermatolog Treat, 2020,31（2）:168⁃174. doi: 10. 1080/09546634.2019.1623368. |
| ［16］ | Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:53⁃62. doi: 10.1038/jidsymp.2011.6. |
| ［17］ | Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea⁃affected skin［J］. Arch Dermatol Res, 2012,304（2）:133⁃137. doi: 10.1007/s00403⁃011⁃1177⁃1. |
| ［18］ | Báez A, Paleari J, Durán MN, et al. Frey syndrome secondary to submaxillectomy and botulinic treatment［J］. Medicina （B Aires）, 2007,67（5）:478⁃480. |
| ［19］ | Khan TT, Herne K, Dayan SH, et al. Facial blanching due to neurotoxins: proposed mechanisms［J］. Dermatol Surg, 2013,39（1 Pt 1）:24⁃29. doi: 10.1111/dsu.12057. |
| ［20］ | Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea［J］. F1000Res, 2018,7:1885. doi: 10. 12688/f1000research.16537.1. |
| ［21］ | Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action［J］. Arq Neuropsiquiatr, 2005,63（1）:180⁃185. doi: 10.1590/s0004⁃282x2005000100035. |
| ［22］ | Choi JE, Di Nardo A. Skin neurogenic inflammation［J］. Semin Immunopathol, 2018,40（3）:249⁃259. doi: 10.1007/s00281⁃018⁃0675⁃z. |
| ［23］ | Kellogg DL Jr, Zhao JL, Wu Y, et al. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans［J］. J Appl Physiol （1985）, 2012,113（10）:1512⁃1518. doi: 10.1152/japplphysiol.00859.2012. |
| ［24］ | Mascarenhas NL, Wang Z, Chang YL, et al. TRPV4 mediates mast cell activation in cathelicidin⁃induced rosacea inflammation［J］. J Invest Dermatol, 2017,137（4）:972⁃975. doi: 10.1016/j.jid.2016.10.046. |
| ［25］ | Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea［J］. Front Med （Lausanne）, 2019,6:324. doi: 10.3389/fmed.2019.00324. |
| ［26］ | Choi JE, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation［J］. J Dermatol Sci, 2019,93（1）:58⁃64. doi: 10.1016/j.jdermsci.2018.12.004. |
| ［27］ | Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment?［J］. Clin Exp Dermatol, 2018,43（5）:599⁃600. doi: 10.1111/ced.13342. |
| ［28］ | Gheisari M, Moslemi Haghighi S, Baghani M, et al. Generalized drug eruption with vasculopathic reaction pattern to botulinum toxin injection［J］. Dermatol Ther, 2020,33（6）:e14294. doi: 10.1111/dth.14294. |
| ［29］ | Grassegger A. Comment on Tamura et al′s Allergic reaction to botulinum toxin: positive intradermal test［J］. Dermatol Surg, 2009,35（6）:1015. doi: 10.1111/j.1524⁃4725.2009.01176.x. |
| ［30］ | Cohen JL, Scuderi N. Safety and Patient Satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review［J］. Aesthet Surg J, 2017,37（suppl_1）:S32⁃S44. doi: 10.1093/asj/sjx010. |
| ［31］ | Wu W. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects［J］. Plast Reconstr Surg, 2015,136（5 Suppl）:92S⁃100S. doi: 10.1097/PRS.000000 0000001827. |
| ［32］ | Chen Y, Hua W, Li A, et al. Analysis of facial redness by comparing VISIA（®） from Canfield and CSKIN（®） from Yanyun Technology［J］. Skin Res Technol, 2020,26（5）:696⁃701. doi: 10.1111/srt.12856. |
| ［33］ | Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long⁃lasting results［J］. Br J Dermatol, 2008,159（3）:628⁃632. doi: 10.1111/j.1365⁃2133.2008.08702.x. |
| ［34］ | Carruthers J, Carruthers A. The effect of full⁃face broadband light treatments alone and in combination with bilateral crow′s feet Botulinum toxin type A chemodenervation［J］. Dermatol Surg, 2004,30（3）:355⁃366. doi: 10.1111/j.1524⁃4725.2004. 30101.x. |
| ［35］ | Khoury JG, Saluja R, Goldman MP. The effect of botulinum toxin type A on full⁃face intense pulsed light treatment: a randomized, double⁃blind, split⁃face study［J］. Dermatol Surg, 2008,34（8）:1062⁃1069. doi: 10.1111/j.1524⁃4725.2008.34207.x. |
| ［36］ | Al⁃Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type⁃A in the treatment of rosacea⁃associated erythema and flushing［J］. Dermatol Ther, 2020,33（6）:e13976. doi: 10.1111/dth.13976. |
| ［37］ | Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349. |
| [1] | 洪芷榆 谢红付 李吉 黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128. |
| [2] | 任芬芬 王鹏 张景展 康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 0(3): 20220140-e20220140. |
| [3] | 陈启韬 李煜乾 邵光辉 朱晶 朱麒麟 李中明 杜旭峰 范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210803-e20210803. |
| [4] | 杜方智 张栩 王千秋. 猴痘的临床表现与诊疗随访[J]. 中华皮肤科杂志, 2023, 56(1): 76-81. |
| [5] | 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023, 56(1): 5-15. |
| [6] | 迪丽达尔·亚森 梅星星 周晖 陈小红 唐旭华. 肺炎支原体诱导的皮疹和黏膜炎8例临床特征及预后分析[J]. 中华皮肤科杂志, 2022, 55(9): 767-771. |
| [7] | 樊碧娆 陈喜雪 王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681. |
| [8] | 曹淼 崇杉 胡新媛 朱学骏 王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675. |
| [9] | 晋亮 刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739. |
| [10] | 徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652. |
| [11] | 王媛 李志量 李锁 荆可 孙超 梁桂熔 张寒梅 冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561. |
| [12] | 高子蕊 赵培 窦沅青 刘萍 张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565. |
| [13] | 王玲艳 潘靖 苗钢 常晓丹 金秋子 郭宁宁 张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587. |
| [14] | 张宁 李舒 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609. |
| [15] | 吕莎 王爽 武寒飞 张明瑞 胡馨 李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632. |
|
